Pacira BioSciences, Inc. (PCRX)
USD 24.38
(2.91%)
USD 24.38
(2.91%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 513.79 Million USD | -28.7% |
| 2022 | 720.62 Million USD | -3.43% |
| 2021 | 746.25 Million USD | 94.31% |
| 2020 | 384.05 Million USD | 10.68% |
| 2019 | 346.98 Million USD | 19.41% |
| 2018 | 290.59 Million USD | 5.22% |
| 2017 | 276.17 Million USD | 153.98% |
| 2016 | 108.73 Million USD | 2.65% |
| 2015 | 105.92 Million USD | 2.74% |
| 2014 | 103.1 Million USD | 4.18% |
| 2013 | 98.96 Million USD | 279.92% |
| 2012 | 26.04 Million USD | 29.76% |
| 2011 | 20.07 Million USD | -8.21% |
| 2010 | 21.86 Million USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 511.68 Million USD | -0.41% |
| 2024 Q2 | 589.3 Million USD | 15.17% |
| 2023 Q1 | 605.36 Million USD | -16.0% |
| 2023 Q3 | 573.03 Million USD | -3.24% |
| 2023 Q2 | 592.22 Million USD | -2.17% |
| 2023 FY | 513.79 Million USD | -28.7% |
| 2023 Q4 | 513.79 Million USD | -10.34% |
| 2022 Q3 | 779.4 Million USD | -1.27% |
| 2022 Q4 | 720.62 Million USD | -7.54% |
| 2022 FY | 720.62 Million USD | -3.43% |
| 2022 Q1 | 799.45 Million USD | 7.13% |
| 2022 Q2 | 789.45 Million USD | -1.25% |
| 2021 Q3 | 392.93 Million USD | 0.77% |
| 2021 FY | 746.25 Million USD | 94.31% |
| 2021 Q1 | 387 Million USD | 0.77% |
| 2021 Q4 | 746.25 Million USD | 89.92% |
| 2021 Q2 | 389.94 Million USD | 0.76% |
| 2020 Q1 | 350.26 Million USD | 0.95% |
| 2020 Q2 | 388.07 Million USD | 10.79% |
| 2020 Q3 | 528.91 Million USD | 36.29% |
| 2020 Q4 | 384.05 Million USD | -27.39% |
| 2020 FY | 384.05 Million USD | 10.68% |
| 2019 Q3 | 340.96 Million USD | 1.11% |
| 2019 Q4 | 346.98 Million USD | 1.77% |
| 2019 Q2 | 337.22 Million USD | 4.19% |
| 2019 Q1 | 323.65 Million USD | 11.38% |
| 2019 FY | 346.98 Million USD | 19.41% |
| 2018 Q4 | 290.59 Million USD | 1.29% |
| 2018 FY | 290.59 Million USD | 5.22% |
| 2018 Q3 | 286.89 Million USD | 1.28% |
| 2018 Q2 | 283.25 Million USD | 1.28% |
| 2018 Q1 | 279.68 Million USD | 1.27% |
| 2017 Q2 | 269.32 Million USD | 1.25% |
| 2017 Q1 | 265.99 Million USD | 144.62% |
| 2017 Q3 | 272.72 Million USD | 1.26% |
| 2017 FY | 276.17 Million USD | 153.98% |
| 2017 Q4 | 276.17 Million USD | 1.27% |
| 2016 FY | 108.73 Million USD | 2.65% |
| 2016 Q1 | 105.21 Million USD | -0.67% |
| 2016 Q3 | 107.56 Million USD | 1.1% |
| 2016 Q4 | 108.73 Million USD | 1.09% |
| 2016 Q2 | 106.38 Million USD | 1.11% |
| 2015 Q1 | 104.13 Million USD | 1.0% |
| 2015 Q4 | 105.92 Million USD | 0.97% |
| 2015 FY | 105.92 Million USD | 2.74% |
| 2015 Q2 | 103.88 Million USD | -0.24% |
| 2015 Q3 | 104.9 Million USD | 0.98% |
| 2014 Q2 | 101.03 Million USD | 1.04% |
| 2014 Q4 | 103.1 Million USD | 1.01% |
| 2014 Q1 | 99.99 Million USD | 1.05% |
| 2014 FY | 103.1 Million USD | 4.18% |
| 2014 Q3 | 102.06 Million USD | 1.02% |
| 2013 Q4 | 98.96 Million USD | 1.06% |
| 2013 FY | 98.96 Million USD | 279.92% |
| 2013 Q3 | 97.92 Million USD | 1.07% |
| 2013 Q2 | 96.89 Million USD | 1.08% |
| 2013 Q1 | 95.85 Million USD | 268.0% |
| 2012 Q4 | 26.04 Million USD | 0.92% |
| 2012 Q1 | 25.07 Million USD | 24.91% |
| 2012 FY | 26.04 Million USD | 29.76% |
| 2012 Q2 | 24.67 Million USD | -1.61% |
| 2012 Q3 | 25.81 Million USD | 4.63% |
| 2011 Q4 | 20.07 Million USD | -2.57% |
| 2011 Q2 | 22.57 Million USD | 15.37% |
| 2011 Q1 | 19.57 Million USD | -10.51% |
| 2011 Q3 | 20.6 Million USD | -8.75% |
| 2011 FY | 20.07 Million USD | -8.21% |
| 2010 Q3 | 53.9 Million USD | 858.26% |
| 2010 FY | 21.86 Million USD | 0.0% |
| 2010 Q4 | 21.86 Million USD | -59.43% |
| 2010 Q2 | 5.62 Million USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bright Green Corporation | 201.78 Thousand USD | -254527.991% |
| Alpha Teknova, Inc. | 13.25 Million USD | -3777.413% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | -65.918% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -464.14% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | -4.864% |
| Cosmos Health Inc. | 3.03 Million USD | -16827.126% |
| Journey Medical Corporation | 14.62 Million USD | -3413.856% |
| Embecta Corp. | 1.62 Billion USD | 68.39% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -2.442% |
| Dynavax Technologies Corporation | 252.41 Million USD | -103.55% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -3755.591% |
| PainReform Ltd. | 30 Thousand USD | -1712553.333% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -95217.744% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -95217.744% |
| SCYNEXIS, Inc. | 12.15 Million USD | -4125.644% |
| Safety Shot Inc | 304.9 Thousand USD | -168409.086% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -438558.232% |
| Procaps Group, S.A. | 28.41 Million USD | -1708.504% |
| Theratechnologies Inc. | 51.26 Million USD | -902.314% |
| Harrow Health, Inc. | 183.17 Million USD | -180.499% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -590470.115% |
| Biofrontera Inc. | 804 Thousand USD | -63804.975% |
| DURECT Corporation | 2.7 Million USD | -18915.396% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1447.765% |
| Cronos Group Inc. | 1.55 Million USD | -32856.767% |
| OptiNose, Inc. | 611 Thousand USD | -83990.998% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | -3.108% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1402.767% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -112822.198% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -745.824% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -3919.01% |
| Radius Health, Inc. | 339.66 Million USD | -51.266% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -4908.735% |
| Phibro Animal Health Corporation | 458.28 Million USD | -12.112% |
| Procaps Group S.A. | 28.41 Million USD | -1708.504% |
| Alvotech | 1.02 Billion USD | 50.008% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -7765.83% |
| Viatris Inc. | 16.18 Billion USD | 96.826% |
| Rockwell Medical, Inc. | 8.29 Million USD | -6095.539% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -4623.692% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -152819.572% |
| Tilray Brands, Inc. | 287.93 Million USD | -78.442% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -326.351% |
| Shineco, Inc. | 10.01 Million USD | -5029.07% |
| PetIQ, Inc. | 437.82 Million USD | -17.353% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -244564.762% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -98.914% |
| Alimera Sciences, Inc. | 64.48 Million USD | -696.719% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -1234.05% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -380238.888% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -7392.617% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -71260.556% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2285062.782% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -1468.364% |
| Hempacco Co., Inc. | 5.93 Million USD | -8562.888% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 50.008% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -813.968% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 16.608% |
| Currenc Group, Inc. | 2.5 Million USD | -20394.668% |
| Kamada Ltd. | 7.43 Million USD | -6807.717% |
| Indivior PLC | 235.66 Million USD | -118.018% |
| Evoke Pharma, Inc. | 5 Million USD | -10175.92% |
| Flora Growth Corp. | 942 Thousand USD | -54443.1% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2285062.782% |
| Evolus, Inc. | 120.35 Million USD | -326.886% |
| HUTCHMED (China) Limited | 48.18 Million USD | -966.21% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 12.798% |
| Akanda Corp. | 2.49 Million USD | -20475.255% |